Form 4: Absci SVP Granted Significant Equity Awards

Absci Corp's SVP, CAO Todd Bedrick received significant equity awards, including Restricted Stock Units and stock options, with vesting tied to continued service.

Summary

• Todd Bedrick, SVP, CAO of Absci Corp, was granted 49,600 Restricted Stock Units (RSUs) on March 2, 2026, under the Absci Corporation 2021 Stock Option and Incentive Plan.
• These RSUs will vest in three substantially equal annual installments, with the first installment vesting on March 1, 2027, contingent on continuous service.
• Bedrick also acquired 195,900 stock options on March 2, 2026, with an exercise price of $2.8 per share.
• The stock options will vest over a three-year period in substantially equal annual installments, with the first installment vesting on March 1, 2027, also subject to continuous service.
• On March 3, 2026, 5,282 shares of common stock were disposed of at a price of $2.8 per share to cover tax withholding obligations related to the vesting of restricted stock units, which was not a discretionary trade.
• Following these transactions, Bedrick beneficially owns 216,942 shares of common stock and 195,900 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive, routine event. The equity grants align executive interests with shareholders, which is generally favorable, but it's a standard compensation practice rather than a significant new development.

Positives

• The grant of Restricted Stock Units and stock options aligns executive compensation with shareholder interests, incentivizing long-term performance and retention.
• The equity awards demonstrate the company's commitment to its executive team and their continued contribution.

Negatives

• The disposition of 5,282 shares for tax withholding, while a routine event, represents a reduction in direct share ownership, though it was not a discretionary sale.

Future Outlook

The equity awards are structured with future vesting schedules, indicating a long-term incentive for the reporting person. The RSUs and stock options will vest in substantially equal annual installments, with the first vesting on March 1, 2027, contingent on continuous service to the Issuer.

Management Comments

• The equity grants are intended to incentivize the Senior Vice President and Chief Accounting Officer, Todd Bedrick, through long-term alignment with company performance and shareholder value.

Industry Context

StockSavvy.ai notes that the granting of Restricted Stock Units and stock options to key executives is a standard practice across industries, particularly in biotechnology and technology sectors, to attract, retain, and motivate talent. These awards are designed to align management's interests with those of shareholders by tying compensation to the company's long-term stock performance and the executive's continued service.

Comparison to Industry Standards

• Equity compensation, including RSUs and stock options with multi-year vesting schedules, is a common component of executive compensation packages in the biotechnology and pharmaceutical industries, similar to practices at companies like Moderna, BioNTech, or Regeneron Pharmaceuticals.
• The vesting schedule of three substantially equal annual installments is a typical structure aimed at promoting long-term retention and performance, consistent with global benchmarks for executive incentive plans.

Stakeholder Impact

• Shareholders: The equity grants are designed to align the interests of a key executive with shareholders, potentially leading to improved long-term company performance and value creation.
• Employees: The compensation structure for executives can set a precedent or reflect the company's overall approach to employee incentives, potentially impacting morale and retention.

Next Steps

• The Restricted Stock Units and stock options will begin vesting in annual installments, with the first on March 1, 2027, subject to Todd Bedrick's continuous service.

Key Dates

Recommendation

This Form 4 filing reports a routine executive equity grant and a non-discretionary tax-related share disposition. While the equity grant is a positive for executive alignment, it does not present new fundamental information that would significantly alter an investment thesis or warrant a change in recommendation. It is an expected part of executive compensation.

Keywords

Absci, ABSI, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation, SVP CAO